UY37752A - Proteínas de unión al antígeno anti-jagged1 - Google Patents
Proteínas de unión al antígeno anti-jagged1Info
- Publication number
- UY37752A UY37752A UY0001037752A UY37752A UY37752A UY 37752 A UY37752 A UY 37752A UY 0001037752 A UY0001037752 A UY 0001037752A UY 37752 A UY37752 A UY 37752A UY 37752 A UY37752 A UY 37752A
- Authority
- UY
- Uruguay
- Prior art keywords
- jagged1
- union
- proteins
- antigen anti
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000049556 Jagged-1 Human genes 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan métodos para tratar afecciones relacionadas con enfermedad pulmonar mediante el uso de una proteína de unión al antígeno específica para el polipéptido Jagged1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762512805P | 2017-05-31 | 2017-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37752A true UY37752A (es) | 2019-01-02 |
Family
ID=62683483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037752A UY37752A (es) | 2017-05-31 | 2018-05-31 | Proteínas de unión al antígeno anti-jagged1 |
Country Status (23)
Country | Link |
---|---|
US (3) | US11028180B2 (es) |
EP (1) | EP3630820A1 (es) |
JP (1) | JP7222614B2 (es) |
KR (1) | KR20200012848A (es) |
CN (1) | CN110621695B (es) |
AR (1) | AR111767A1 (es) |
AU (1) | AU2018275231A1 (es) |
BR (1) | BR112019023118A2 (es) |
CA (1) | CA3059975A1 (es) |
CL (1) | CL2019003167A1 (es) |
CO (1) | CO2019012204A2 (es) |
CR (1) | CR20190513A (es) |
EA (1) | EA201992348A1 (es) |
JO (1) | JOP20190259A1 (es) |
MA (1) | MA48777A (es) |
MX (1) | MX2019013211A (es) |
PE (1) | PE20200487A1 (es) |
PH (1) | PH12019502449A1 (es) |
SG (1) | SG11201909529XA (es) |
TW (1) | TW201908339A (es) |
UY (1) | UY37752A (es) |
WO (1) | WO2018222770A1 (es) |
ZA (1) | ZA201906821B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI631135B (zh) * | 2014-02-12 | 2018-08-01 | 建南德克公司 | 抗jagged1抗體及使用方法 |
JOP20190259A1 (ar) * | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
CN111471643B (zh) * | 2020-04-09 | 2020-12-29 | 创芯国际生物科技(广州)有限公司 | 一种通用型上呼吸道粘膜类器官的培养基及培养方法 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3126980B2 (ja) | 1991-03-11 | 2001-01-22 | ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド | レニラ(renilla)ルシフェラーゼのクローニング及び発現 |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
AU2249592A (en) | 1991-06-14 | 1993-01-12 | Dnx Corporation | Production of human hemoglobin in transgenic pigs |
JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
US6004924A (en) | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
JP3810791B2 (ja) | 1993-09-10 | 2006-08-16 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 緑色蛍光タンパク質の使用 |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
CA2271717A1 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6136952A (en) * | 1997-06-25 | 2000-10-24 | University Of Washington | Human jagged polypeptide, encoding nucleic acids and methods of use |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
EP1064360B1 (en) | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
EP2260058A2 (en) * | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
WO2012106529A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Jagged1 as a marker and therapeutic target for breast cancer bone metastasis |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
WO2013192550A2 (en) * | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
JP6352264B2 (ja) * | 2012-08-13 | 2018-07-04 | ジェネンテック, インコーポレイテッド | 抗jagged抗体および使用方法 |
US10350216B2 (en) * | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
GB201300706D0 (en) | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
US9550829B2 (en) * | 2013-03-15 | 2017-01-24 | Genentech, Inc. | Compositions and methods for diagnosis and treatment of hepatic cancers |
TWI631135B (zh) | 2014-02-12 | 2018-08-01 | 建南德克公司 | 抗jagged1抗體及使用方法 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
KR101599370B1 (ko) | 2014-04-24 | 2016-03-03 | 한국생명공학연구원 | Jagged 1에 대한 인간 단일클론항체 J1J22 |
CN107922487A (zh) * | 2015-03-06 | 2018-04-17 | 索伦托治疗有限公司 | 结合jag1的抗体治疗剂 |
JOP20190259A1 (ar) * | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
-
2017
- 2017-06-16 JO JOP/2019/0259A patent/JOP20190259A1/ar unknown
-
2018
- 2018-05-30 KR KR1020197032633A patent/KR20200012848A/ko not_active Application Discontinuation
- 2018-05-30 CA CA3059975A patent/CA3059975A1/en active Pending
- 2018-05-30 EP EP18732590.7A patent/EP3630820A1/en active Pending
- 2018-05-30 MX MX2019013211A patent/MX2019013211A/es unknown
- 2018-05-30 BR BR112019023118-8A patent/BR112019023118A2/pt unknown
- 2018-05-30 WO PCT/US2018/035209 patent/WO2018222770A1/en active Application Filing
- 2018-05-30 CR CR20190513A patent/CR20190513A/es unknown
- 2018-05-30 AU AU2018275231A patent/AU2018275231A1/en active Pending
- 2018-05-30 CN CN201880029832.2A patent/CN110621695B/zh active Active
- 2018-05-30 US US15/993,448 patent/US11028180B2/en active Active
- 2018-05-30 MA MA048777A patent/MA48777A/fr unknown
- 2018-05-30 SG SG11201909529X patent/SG11201909529XA/en unknown
- 2018-05-30 PE PE2019002278A patent/PE20200487A1/es unknown
- 2018-05-30 EA EA201992348A patent/EA201992348A1/ru unknown
- 2018-05-31 AR ARP180101447A patent/AR111767A1/es unknown
- 2018-05-31 TW TW107118769A patent/TW201908339A/zh unknown
- 2018-05-31 UY UY0001037752A patent/UY37752A/es not_active Application Discontinuation
- 2018-05-31 JP JP2018104357A patent/JP7222614B2/ja active Active
-
2019
- 2019-10-16 ZA ZA2019/06821A patent/ZA201906821B/en unknown
- 2019-10-29 PH PH12019502449A patent/PH12019502449A1/en unknown
- 2019-10-30 CO CONC2019/0012204A patent/CO2019012204A2/es unknown
- 2019-11-04 CL CL2019003167A patent/CL2019003167A1/es unknown
-
2021
- 2021-05-13 US US17/320,128 patent/US11897963B2/en active Active
-
2022
- 2022-02-16 US US17/672,889 patent/US11897965B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20190023802A1 (en) | 2019-01-24 |
PE20200487A1 (es) | 2020-03-03 |
MA48777A (fr) | 2020-04-08 |
MX2019013211A (es) | 2020-07-27 |
WO2018222770A1 (en) | 2018-12-06 |
JP7222614B2 (ja) | 2023-02-15 |
EA201992348A1 (ru) | 2020-03-24 |
CL2019003167A1 (es) | 2020-03-20 |
CN110621695B (zh) | 2023-10-17 |
TW201908339A (zh) | 2019-03-01 |
US11897965B2 (en) | 2024-02-13 |
BR112019023118A2 (pt) | 2020-10-20 |
AR111767A1 (es) | 2019-08-14 |
US20220169744A1 (en) | 2022-06-02 |
JOP20190259A1 (ar) | 2019-10-31 |
ZA201906821B (en) | 2021-06-30 |
SG11201909529XA (en) | 2019-11-28 |
US20210340270A1 (en) | 2021-11-04 |
US11897963B2 (en) | 2024-02-13 |
CN110621695A (zh) | 2019-12-27 |
CR20190513A (es) | 2020-01-17 |
EP3630820A1 (en) | 2020-04-08 |
PH12019502449A1 (en) | 2020-07-20 |
JP2018203735A (ja) | 2018-12-27 |
CA3059975A1 (en) | 2018-12-06 |
CO2019012204A2 (es) | 2020-02-07 |
KR20200012848A (ko) | 2020-02-05 |
AU2018275231A1 (en) | 2019-10-31 |
US11028180B2 (en) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
MX2017012352A (es) | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. | |
EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
EA202092202A1 (ru) | Конструкции антител к ror | |
MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
EA202190807A1 (ru) | Антитела к синуклеину | |
UY37752A (es) | Proteínas de unión al antígeno anti-jagged1 | |
EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
EA202091577A1 (ru) | Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231103 |